Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Bundamedik TbkISX:BMHS -0.99%75 EV-to-EBITDA is 17.87 as of Sep. 10, 2026, which is 13% above its 10-year median of 15.80. GuruFocus rates ISX:BMHS with a GF Score™ of 75/100 and a GF Value™ of Rp267.49 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 515 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks worse than 73.01% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Bundamedik Tbk's enterprise value is Rp3,420,596 Mil.
PT Bundamedik Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was Rp191,368 Mil. Therefore, PT Bundamedik Tbk's EV-to-EBITDA for today is 17.87.
The historical rank and industry rank for PT Bundamedik Tbk's EV-to-EBITDA or its related term are showing as below:
ISX:BMHS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.74 Med: 15.8 Max: 26.79
Current: 17.87
During the past 8 years, the highest EV-to-EBITDA of PT Bundamedik Tbk was 26.79. The lowest was 9.74. And the median was 15.80.
ISX:BMHS's EV-to-EBITDA is ranked worse than 73.01% of 515
companies
in the Healthcare Providers & Services industry
Industry Median: 10.57
vs ISX:BMHS: 17.87
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Bundamedik Tbk's PE Ratio (TTM) for today is calculated as:
PT Bundamedik Tbk's share price for today is Rp200.00.
PT Bundamedik Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-0.214.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PT Bundamedik Tbk's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, EHC: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's EV-to-EBITDA falls into.
PT Bundamedik Tbk's current Enterprise Value is Rp3,420,596 Mil.
PT Bundamedik Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp191,368 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a EV-to-EBITDA of 17.87 as of Sep. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Bundamedik Tbk. This is 13% above median its historical median of 15.80. Over the past decade, PT Bundamedik Tbk's EV-to-EBITDA has ranged from 9.74 to 26.79. According to the industry distribution chart, PT Bundamedik Tbk ranks #376 out of 515 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is PT Bundamedik Tbk's EV-to-EBITDA too high?
PT Bundamedik Tbk's current EV-to-EBITDA of 17.87 is 13% above median its 10-year median of 15.80. Over the past 10 years, this metric has ranged from a low of 9.74 to a high of 26.79. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.57. PT Bundamedik Tbk's value of 17.87 is 69.1% above this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #376 out of 515 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #376 out of 515 companies for EV-to-EBITDA. This places PT Bundamedik Tbk in the lower half of its industry. The industry median EV-to-EBITDA is 10.57. PT Bundamedik Tbk's value of 17.87 is 69.1% above this benchmark. Historically, PT Bundamedik Tbk's own EV-to-EBITDA has ranged from 9.74 to 26.79 over the past decade. While the company's 10-year median is 15.80 vs. the industry median of 10.57, PT Bundamedik Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.57, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current EV-to-EBITDA of 17.87 is 69.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Bundamedik Tbk. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current EV-to-EBITDA is 17.87, which is 13% above median its own 10-year median of 15.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp267.49, compared to a current price of Rp200.00 — trading 25.2% below its estimated fair value. The current EV-to-EBITDA is 17.87, which is 13% above median its 10-year median of 15.80 and 69.1% above the Healthcare Providers & Services industry median of 10.57. PT Bundamedik Tbk's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current EV-to-EBITDA is 17.87 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp200.00 is trading 25.2% below its estimated GF Value™ of Rp267.49.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
EV-to-EBITDA: 17.87 (13% above median its 10-year median of 15.80)
GF Value™: Rp267.49 vs. price of Rp200.00 (25.2% below fair value)
Industry Position: 69.1% above the Healthcare Providers & Services median (#376 of 515)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
75GF Score
Get the complete analysis for ISX:BMHS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
